ARTICLE | Product Development
Plus readouts from Gritstone, Disc, BMS and Novocure
By Lauren Martz, Executive Director, Biopharma Intelligence
April 3, 2024 12:31 AM UTC
Delivery is still one of the greatest challenges for genetic therapies, and a decision by Verve Therapeutics Inc. (NASDAQ:VERV) to deprioritize its lead base editor proves that even delivery to the liver hasn’t been perfected.
On Tuesday, Verve announced it had paused enrollment in the Phase Ib Heart-1 trial of lead program VERVE-101 after one of six patients with heterozygous familial hypercholesterolemia treated at the 0.45 mg/kg dose experienced a pair of Grade 3 adverse events — liver toxicity and thrombocytopenia…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651984/clinical-report-getting-behind-verve-s-pcsk9-phase-i-safety-signal